These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38762454)

  • 1. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
    Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
    J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
    J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of geriatric nutritional risk index in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Eur J Surg Oncol; 2024 Jun; 50(6):108323. PubMed ID: 38603867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Immunol; 2023; 14():1217967. PubMed ID: 37954582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
    Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CT-based novel model to predict pathological complete response of locally advanced esophageal squamous cell carcinoma to neoadjuvant PD-1 blockade in combination with chemotherapy.
    Zhou HY; Guo WW; Ou J; Li R; Gui Y; Li L; Fu MY; Zhang XM; Chen TW
    Eur J Radiol; 2023 Oct; 167():111065. PubMed ID: 37651827
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
    Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
    Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
    Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
    Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.
    Fan L; Yang Z; Chang M; Chen Z; Wen Q
    J Transl Med; 2024 Jun; 22(1):579. PubMed ID: 38890720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
    Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
    Front Immunol; 2022; 13():836338. PubMed ID: 35300335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.
    Gao L; Hong ZN; Wu L; Yang Y; Kang M
    Front Immunol; 2022; 13():1008681. PubMed ID: 36569913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Front Immunol; 2022; 13():1015365. PubMed ID: 36505443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):272-283. PubMed ID: 37838648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy.
    Zhao Y; Xia M; Dang Y; Li Y; Zhao X; Kang N; Zuo J; Zhang R
    Ann Ital Chir; 2024; 95(3):284-293. PubMed ID: 38918965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
    Chen P; Wang L; Yang X; Feng J
    Biomol Biomed; 2024 Jan; 24(1):159-169. PubMed ID: 37597214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
    Yang Y; Yi Y; Wang Z; Li S; Zhang B; Sang Z; Zhang L; Cao Q; Li B
    BMC Cancer; 2024 Apr; 24(1):460. PubMed ID: 38609892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
    Wu YY; Dai L; Yang YB; Yan WP; Cheng H; Fan MY; Gao YM; Chen KN
    Ann Surg Oncol; 2024 Aug; 31(8):5047-5054. PubMed ID: 38172446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.